Actions

Newsfeed Popular Local Discover Follows Blocks Bookmarks Filters Settings PowerUps Help Updates

prnewswire.com / Share Newsitem

View, share or embed this newsitem using the details below.

PR Newswire: press release distribution, targeting, monitoring and marketing

FDA approves Alhemo injection as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12

FDA approval is based on data from the pivotal phase 3 trial (explorer7) establishing the safety and efficacy of Alhemo for daily prevention of bleeds in adults and pediatric patients 12 years of age and older living with hemophilia A or B with

https://newsreadery.com/go/bbd54cef5e2719603cd2fc5562f8e957

Save

Back

Read Full Article